12:00 AM
Mar 24, 2003
 |  BioCentury  |  Tools & Techniques

Hypnotizing insomniac investors

Hypnion Inc. is taking something old and something new to create what it believes will be a lower-risk model for drug development. The "something old" part is the creation of analogs of marketed drugs. The "something new" is the use of its Score-2000 high throughput in vivo assay for real-time preclinical sleep-wake drug discovery. Investors clearly like the idea: last week they put $47.5 million into a series B venture round.

Score-2000 concurrently monitors sleep-wakefulness, sleep architecture and other physiological and behavior...

Read the full 391 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >